Security Snapshot

Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) Institutional Ownership

CUSIP: 45719W205

13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

105

Shares (Excl. Options)

117,856,372

Price

$2.03

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+2,746,635
Value change
+$6,944,245
Number of holders
105
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
135,127,605
SEC-reported price per share
$2.35
Insider filing price
$2.35
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 45719W205.
  • 105 institutions reported positions in Q2 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 104 to 105 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $193,410,814 to $239,197,298.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 105 institutions filings for Q2 2026.

Open SEC evidence

Security key

45719W205

Latest holder period

Q2 2026

13F holders

105

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
IKT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% -38% $29,894,148 -$21,105,852 14,653,994 -41% RA Capital Management, L.P. 29 Jul 2026
Commodore Capital LP 9.9% $25,439,441 14,054,940 Commodore Capital LP 31 Mar 2026
ADAR1 Capital Management, LLC 9.9% 0% $25,086,651 +$2,113,430 13,860,028 +9.2% ADAR1 Capital Management, LLC 31 Mar 2026
Sands Capital Life Sciences Pulse Fund II, L.P. 9.3% -14% $26,558,689 13,018,965 0% Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2026
Fairmount Funds Management LLC 9.9% 0% $24,922,202 +$10,885,052 12,461,101 +78% Fairmount Funds Management LLC 31 Dec 2025
PERCEPTIVE ADVISORS LLC 6.9% -22% $21,054,585 -$4,722,600 10,320,875 -18% Perceptive Advisors LLC 30 Jun 2026
Trails Edge Capital Partners, LP 6.1% +20% $14,583,794 +$3,460,986 8,057,345 +31% Trails Edge Capital Partners, LP 31 Mar 2026
BlackRock, Inc. 5.9% $15,770,602 7,768,004 BlackRock, Inc. 30 Jun 2026
Nantahala Capital Management, LLC 4.3% -23% $11,853,393 -$2,503,955 5,810,487 -17% Nantahala Capital Management, LLC 30 Jun 2026
ARMISTICE CAPITAL, LLC 5% $7,975,554 3,529,006 Armistice Capital, LLC 31 Dec 2024

As of 30 Jun 2026, 105 institutional investors reported holding 117,856,372 shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 87% of the company’s total 135,127,605 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
82%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Sands Capital Alternatives, LLC 9.6% 13,018,965 0% 4.3% $26,428,499
Soleus Capital Management, L.P. 8% 10,875,000 0% 0.76% $22,076,250
Trails Edge Capital Partners, LP 6.7% 9,051,318 +12% 2.9% $18,374,176
Fairmount Funds Management LLC 6.4% 8,625,000 0% 1.2% $17,508,750
BlackRock, Inc. 5.7% 7,768,057 +23% 0% $15,769,155
ADAR1 Capital Management, LLC 5.5% 7,387,205 +12% 0.71% $14,996,026
Blackstone Inc. 4.4% 5,938,276 0% 0.04% $12,054,700
Siren, L.L.C. 4.3% 5,850,000 0% 0.24% $11,875,500
Commodore Capital LP 4% 5,397,488 0% 0.65% $10,956,901
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 4,935,354 +11% 0% $10,018,769
MILLENNIUM MANAGEMENT LLC 3% 4,028,102 +38% 0.01% $8,177,047
Saturn V Capital Management LP 2.9% 3,869,056 +0.15% 1.1% $7,854,184
Kalehua Capital Management LLC 2.8% 3,821,890 0% 4.5% $7,758,437
Spruce Street Capital LP 2.7% 3,581,603 0% 1.4% $7,270,654
Squadron Capital Management LLC 2.2% 3,000,000 -14% 2.1% $6,090,000
Nantahala Capital Management, LLC 2% 2,701,863 0% 0.33% $5,484,782
GEODE CAPITAL MANAGEMENT, LLC 1.9% 2,607,129 +20% 0% $5,293,608
STATE STREET CORP 1.4% 1,909,101 +13% 0% $3,875,475
SummitTX Capital, L.P. 1.3% 1,780,262 +17% 0.1% $3,613,932
Integral Health Asset Management, LLC 1% 1,350,000 0% 0.11% $2,740,500
NORTHERN TRUST CORP 0.65% 878,585 +22% 0% $1,783,527
VANGUARD PORTFOLIO MANAGEMENT LLC 0.6% 809,490 +31% 0% $1,643,265
TWO SIGMA INVESTMENTS, LP 0.6% 806,264 -4.9% 0% $1,636,716
SPHERA FUNDS MANAGEMENT LTD. 0.48% 649,309 0.19% $1,318,097
VANGUARD FIDUCIARY TRUST CO 0.45% 607,260 +7.1% 0% $1,232,738

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
14
Latest
Q2 2026
Rows shown
1-14 of 14
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 117,856,372 $239,197,298 +$6,944,245 $2.03 105
2026 Q1 115,144,233 $193,410,814 +$11,923,696 $1.68 104
2025 Q4 106,415,262 $218,151,569 +$72,128,708 $2.05 73
2025 Q3 54,964,771 $89,043,214 +$712,913 $1.62 53
2025 Q2 54,512,097 $106,299,597 +$5,482,917 $1.95 48
2025 Q1 51,462,756 $112,702,942 +$3,027,389 $2.19 47
2024 Q4 50,059,308 $162,691,896 +$161,164,562 $3.25 31
2024 Q3 860,232 $1,118,330 +$30,199 $1.30 11
2024 Q2 836,496 $1,021,038 +$723,392 $1.21 12
2024 Q1 205,558 $443,782 -$62,190 $2.16 12
2023 Q4 235,004 $298,925 -$271,105 $1.27 11
2023 Q3 429,662 $597,627 -$496,803 $1.39 13
2023 Q2 747,138 $2,693,647 +$2,394,678 $3.61 14
2023 Q1 82,817 $54,460 +$54,460 $0.66 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .